FindTrial
Sign In

A Multicenter, Open-Label, Study to Evaluate the Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503545-67-00
Acronym
EBS-101-TD-391
Enrollment
38
Registered
2023-07-31
Start date
2024-04-30
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tourette's Disorder

Brief summary

There are not any endpoints for the study since it is an Open Label study

Interventions

DRUGEcopipam 44.8 mg
DRUGEcopipam 33.6 mg
DRUGEcopipam 67.2 mg
DRUGEcopipam 89.6 mg
DRUGEcopipam 11.2 mg
DRUGEcopipam 22.4 mg

Sponsors

Emalex Biosciences Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to No maximum

Design outcomes

Primary

MeasureTime frame
There are not any endpoints for the study since it is an Open Label study—

Countries

Bulgaria, Denmark, France, Germany, Hungary, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026